Stem cells maintain tissue regeneration throughout life, but their numbers and function decline with age — a common mechanism underlying muscle atrophy (satellite cell loss), blood aging (hematopoietic stem cell myeloid skewing), and intestinal barrier weakening. Reversing stem cell aging is a core goal of regenerative medicine.
## Mesenchymal Stem Cell (MSC) Infusion
MSCs can be isolated from bone marrow, adipose tissue, and umbilical cord blood. They modulate immune function and secrete paracrine factors that activate endogenous repair. Clinical programs:
**Longeveron’s CREMES trial**: MSC infusion in elderly frailty patients (Phase II) showed improvements in 6-minute walk distance, quality of life, and inflammatory markers.
**Cardiac applications**: Multiple MSC trials have shown cardiac function improvements after myocardial infarction, though large Phase III results (including DREAM-HF) have been inconsistent.
**Mechanism**: MSCs appear to act primarily through secreted exosomes and paracrine factors rather than direct differentiation — making cell-free “secretome therapy” an active research direction.
## Young Plasma and Parabiosis-Inspired Studies
Amy Wagers’s group at Stanford (2013) found that transfusing young mouse plasma into old mice improved muscle regeneration, cardiac function, and cognition, identifying GDF11 as one active factor. Subsequent studies identified additional young blood factors (GPLD1, Klotho).
Commercial human trials of young plasma infusion (ages 18–25 into older recipients) were conducted by companies including Alkahest and Ambrosia. In 2019, the FDA warned that young blood transfusions for aging lacked clinical benefit evidence and carried potential risks, halting commercial operations. Scientific investigation continues under stricter oversight.
**Blood dilution research** (Irina Conboy, UC Berkeley): Old mouse plasma contains pro-aging factors (TGF-β, B2M); simply diluting old blood with isotonic solution produced rejuvenating effects comparable to young plasma infusion — suggesting that removing pro-aging factors may matter more than adding young factors.
## Partial Reprogramming
Yamanaka factor expression (Oct4/Sox2/Klf4/c-Myc) converts somatic cells to iPSC-like states. Short-term, partial expression — enough to reset epigenetic aging without causing full dedifferentiation — has rejuvenated mouse retinal function, muscle regeneration, and other tissues in animal models.
Altos Labs (Bezos-backed, $3B raised) and Turn Biotechnologies are developing partial reprogramming therapies — considered the highest-potential, highest-risk track in current anti-aging research.
See [Epigenetic Clocks](https://sunqi.org/epigenetic-clock-biological-age-en/) and [Anti-Aging Drug Pipeline](https://sunqi.org/anti-aging-drugs-pipeline-en/).
—
